M. Graas

发表

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial

P. Neven, A. Goldhirsch, G. Viale, 2020, Clinical Cancer Research.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

P. Neven, R. Gelber, A. Goldhirsch, 2018, The Lancet. Oncology.

Interest for a Systematic Rehabilitation Program Including Physical Exercise and Lifestyle Accompaniment for Women Recently Treated for Early Breast Cancer: A Comparative Study

C. Focan, M. Graas, J. Lobelle, 2020, AntiCancer Research.

The Sentinel Lymph Node Biopsy in Breast Cancer

C. Focan, C. Wahlen, B. Dallemagne, 2002, Acta chirurgica Belgica.

Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 study.

F. Kreutz, C. Focan, M. Graas, 2013, Pathologie-biologie.

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer

P. Neven, M. Campone, D. Hayes, 2016, Clinical Cancer Research.

Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

P. Neven, S. Loi, S. Loibl, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

P. Neven, R. Gelber, H. Gómez, 2019, British Journal of Cancer.

Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

H. Denys, C. Vulsteke, N. Ben-Baruch, 2020, Breast Cancer Research and Treatment.

Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.

J. Canon, G. Jerusalem, C. Focan, 2005, Anticancer research.

Mindfulness for the management of cachectic cancer patients: Arandomized study

C. Focan, M. Graas, G. Houbiers, 2016 .

Integration of Chronobiological Concepts for NSCLC Management

C. Focan, M. Bourhaba, M. Graas, 2019, Chronobiology - The Science of Biological Time Structure.

Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.

R. Greil, A. Schneeweiss, J. Baselga, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.

J. Canon, J. Vansteenkiste, P. Vuylsteke, 2015, Lung cancer.

Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group

I. Vergote, L. Dirix, H. Denys, 2022, International Journal of Gynecological Cancer.

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

P. Neven, R. Bose, H. Rugo, 2021, Breast Cancer Research and Treatment.

Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial

A. Schneeweiss, J. Baselga, A. Zubel, 2010 .

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

P. Neven, R. Gelber, H. Gómez, 2019, British Journal of Cancer.

[Hemolytic uremic syndrome induced by gemcitabine. A poorly recognized complication?].

C. Focan, M. Graas, G. Demolin, 2012, Revue medicale de Liege.

[Clozapine in the treatment of mental manifestations of Parkinson disease].

N. Diederich, M. Graas, M. Keipes, 1995, Revue neurologique.

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients.

J. Canon, J. Vansteenkiste, Yali Fu, 2013 .

Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg

P. Vuylsteke, C. Vulsteke, M. Graas, 2019, Acta clinica Belgica.

Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).

P. Neven, M. Campone, D. Hayes, 2014 .